Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DILOR-400 vs AEROLONE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Phosphodiesterase inhibitor; inhibits PDE4 and PDE5, leading to increased intracellular c AMP and c GMP, resulting in bronchodilation and vasodilation.
Selective beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing cyclic AMP production via adenylate cyclase activation.
FDA-approved: Symptomatic management of chronic obstructive pulmonary disease (COPD) and other bronchospastic disorders.,Off-label: Treatment of bronchial asthma, pulmonary hypertension, and as an adjunct in heart failure.
Treatment of bronchospasm in patients with COPD,Long-term maintenance treatment of asthma
400 mg orally every 6 to 8 hours; maximum daily dose 2400 mg.
AEROLONE is not a recognized drug; no standard dosing available.
3.1 hours (terminal elimination half-life; may increase in hepatic impairment or congestive heart failure)
Terminal elimination half-life is approximately 12-15 hours in adults; prolonged to 24-30 hours in severe renal impairment (Cr Cl <30 m L/min).
Hepatic metabolism via CYP1A2, CYP3A4, and CYP2E1; undergoes N-demethylation and oxidation to inactive metabolites.
Primarily metabolized by CYP3A4 and to a lesser extent CYP2D6, with conjugation to inactive metabolites.
Renal (70% unchanged), hepatic metabolism (30%)
Primarily renal excretion of unchanged drug (approximately 65%) and hepatic metabolism (35%), with metabolites excreted in urine and feces. Biliary/fecal elimination accounts for <10%.
40% bound, primarily to albumin
Approximately 88% bound, primarily to albumin and alpha-1-acid glycoprotein.
0.5 L/kg (approximates total body water; indicates distribution into extracellular fluid)
3.5-5.0 L/kg, indicating extensive extravascular distribution and tissue binding.
Oral: 95-100% (well absorbed from gastrointestinal tract)
Oral: 35-50% (first-pass metabolism); Inhalation: 15-30% (dependent on device and technique); Intravenous: 100%.
GFR 10-50 m L/min: 400 mg every 8-12 hours; GFR <10 m L/min: 400 mg every 12-24 hours.
No data; not applicable.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: 400 mg every 8-12 hours; Child-Pugh Class C: 400 mg every 12-24 hours.
No data; not applicable.
6 months to 2 years: 8-12 mg/kg/day divided every 6 hours; 2-12 years: 12-16 mg/kg/day divided every 6 hours; maximum 600 mg/day.
No data; not applicable.
Start at lower end of dosing range (400 mg every 8 hours) and titrate based on renal function and tolerability.
No data; not applicable.
None.
None
Cardiovascular: May cause hypotension, tachycardia, or arrhythmias; use with caution in patients with cardiovascular disease.,CNS: May cause insomnia, anxiety, or seizures; adjust dose in elderly or with hepatic impairment.,Renal: Excreted largely unchanged; caution in renal impairment.,Drug interactions: Increased toxicity with cimetidine, ciprofloxacin, and others that inhibit CYP1A2.
Paradoxical bronchospasm,Cardiovascular effects (e.g., increased heart rate, QT prolongation),Hypokalemia,Hyperglycemia
Hypersensitivity to dyphylline or any xanthine derivative.,Acute myocardial infarction.,Hypotension.,Uncontrolled arrhythmias.
Hypersensitivity to arformoterol or any component of the formulation
Avoid high-caffeine foods (coffee, tea, cola, chocolate) as they increase risk of side effects. Charcoal-broiled foods may decrease drug absorption. High-fat meals may delay absorption; take on an empty stomach for consistent effect.
No significant food interactions. Avoid grapefruit juice as it may affect metabolism of the corticosteroid component.
Teratogenic potential: Pregnancy Category C. First trimester: Limited human data, animal studies show fetal toxicity at high doses. Second and third trimesters: Potential for transient neonatal hypoglycemia, tachycardia, and irritability due to maternal xanthine exposure. Avoid use unless benefit outweighs risk.
No evidence of teratogenicity in animal studies at doses up to 10 mg/kg/day (approximately 120 times the maximum recommended human daily inhaled dose). In humans, no controlled studies exist; however, data from postmarketing reports do not suggest an increased risk of structural anomalies. First trimester: limited data preclude definitive risk assessment, but no pattern of major birth defects has emerged. Second and third trimesters: no known fetal harm from inhaled doses; however, potential for fetal adrenal suppression with prolonged high-dose systemic exposure.
Diphylline (active ingredient) is excreted into breast milk. M/P ratio not established. Potential for irritability and sleep disturbance in infants. Caution advised; consider alternative therapies.
Unknown whether fluticasone propionate is excreted in human breast milk. Other corticosteroids are excreted in breast milk in low amounts, and inhaled doses result in negligible systemic levels, predicting unlikely significant infant exposure. M/P ratio not determined. Caution advised; weigh risk of maternal obstructive airway disease exacerbation against potential infant risks (adrenal suppression, growth retardation).
No well-established pharmacokinetic studies in pregnancy. However, plasma clearance of xanthines may decrease in late pregnancy due to reduced hepatic metabolism. Consider monitoring drug levels and adjusting dose to maintain therapeutic range. Initiate at lower end of dosing, titrate based on response and toxicity.
No specific dose adjustment required based on pharmacokinetic changes; pregnancy may cause decreased airway reactivity but no significant changes in fluticasone clearance. Maintain lowest effective dose to control asthma. No dose increase recommended solely due to pregnancy. Monitor asthma control and adjust dose as per standard guidelines.
DILOR-400 (diprophylline) is a xanthine bronchodilator with similar efficacy to theophylline but with reduced central nervous system stimulation. Monitor serum levels for therapeutic range (10-20 mcg/m L). Caution in patients with peptic ulcer disease, hyperthyroidism, or seizure disorders. Adjust dose in hepatic impairment and elderly. Avoid concurrent use with other xanthines.
AEROLONE is a combination inhaler containing an inhaled corticosteroid (fluticasone propionate) and a long-acting beta2-agonist (salmeterol). Advise patients to rinse mouth with water after each use to reduce risk of oral candidiasis. Not for acute bronchospasm; use a rescue inhaler (short-acting beta agonist) as needed. Monitor for increased heart rate, palpitations, or tremor. Do not stop abruptly; taper dose under medical supervision if discontinuing.
Take exactly as prescribed; do not exceed recommended dose.,Do not crush or chew extended-release tablets.,Report nausea, vomiting, palpitations, or seizures immediately.,Avoid caffeine-containing foods and beverages.,Do not smoke or stop smoking without consulting doctor as dose may need adjustment.,Keep a regular dosing schedule; do not double up missed doses.
Use AEROLONE exactly as prescribed; do not exceed recommended dose.,Rinse your mouth with water after each use (do not swallow) to prevent thrush.,This medication is not for sudden breathing problems; always keep your rescue inhaler (e.g., albuterol) with you.,Do not stop using this medicine without talking to your doctor, as stopping suddenly may worsen your breathing.,Seek immediate medical help if you experience worsening asthma, chest pain, or allergic reaction.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DILOR-400 vs AEROLONE, answered by our medical review team.
DILOR-400 is a Bronchodilator that works by Phosphodiesterase inhibitor; inhibits PDE4 and PDE5, leading to increased intracellular c AMP and c GMP, resulting in bronchodilation and vasodilation.. AEROLONE is a Bronchodilator that works by Selective beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing cyclic AMP production via adenylate cyclase activation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DILOR-400 and AEROLONE depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DILOR-400 is: 400 mg orally every 6 to 8 hours; maximum daily dose 2400 mg.. The standard adult dose of AEROLONE is: AEROLONE is not a recognized drug; no standard dosing available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DILOR-400 and AEROLONE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DILOR-400 is classified as Category C. Teratogenic potential: Pregnancy Category C. First trimester: Limited human data, animal studies show fetal toxicity at high doses. Second and third trimesters: Potential for trans. AEROLONE is classified as Category C. No evidence of teratogenicity in animal studies at doses up to 10 mg/kg/day (approximately 120 times the maximum recommended human daily inhaled dose). In humans, no controlled stu. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.